# | References | Target population | Type of analysis/perspective | Intervention [type] (# of forms) | Model type/time horizon |
---|---|---|---|---|---|
1 | Agartioglu et al. [144] | Fallers aged 65+ admitted to A&E | CEA/PS | HAM | DT/1Â year |
2 | Albert et al. [145] | CD aged 50+ (mean age 75.5) | CUA/PS | MF int. | DT/1Â year |
3 | Alhambra-Borras et al. [146] | CD aged 65+ at high falls risk or frail with no severe physical or cognitive limitation | CUA/PS | Exercise | Markov cohort/lifetime |
4 | Beard et al. [103] | CD aged 60+ | CBA; ROI/PS; Soc | Intersectoral (MC) int.a | BDb/5Â years |
5 | Boyd et al. [109] | Aged 65+ | CUA/PS | Cataract surgery | Markov cohort/20Â years |
6 | Carande-Kulis et al. [97] | CD aged 65+ | ROI/US private health insurance | Exercise (2); MC int. | BD/1Â year |
7 | CSP [96] | CD aged 65+ | ROI/PS | FRS + exercise [PT] | DT/1 year |
8 | Church et al. [89] | CD and residential care, aged 65+ | CEA; CUA/PS | Exercise (3); MC int.; MF int.; MRA; cataract surgery; Med. mod.; cardiac pacing | Markov cohort/10Â years |
9 | Church et al. [90] | CD aged 65+ | CEA; CUA/PS | Exercise (4); MC int.; MF int. (2); MRA; HAM; cataract surgery; Med. mod.; cardiac pacing | Markov cohort/lifetime |
10 | Comans et al. [105] | CD aged 65+, falls history or gait/functional decline, cognitively intact | ROI/Soc | MF int. (2) | BD/1Â year |
11 | Day et al. [104] | CD, characteristics vary by interventionc | CEA/PS; Soc | Exercise (2); HAM; MF int.; Med. mod.; cardiac pacing | DT/1Â year |
12 | Day et al. [93] | CD aged 70+ | CEA/PS; Soc | Exercise [Tai Chi] | DT/1Â year |
13 | Deverall et al. [94] | CD aged 65+ | CUA/PS; Soc | Exercise (3) | Markov cohort/25Â years |
14 | Eldridge et al. [115] | Aged 65+, CD or nursing home | CUA/PS | FRS + MF int. or exercise | DT + Markov cohort/lifetime |
15 | Farag et al. [91] | CD aged 65+, no falls history | CUA/PS | Non-specific int. | Markov cohort/lifetime |
16 | Franklin et al. [92] | CD aged 65+ | CUA/PS | FRS + exercise (3) or HAM | DT + Markov cohort/2 years |
17 | Frick et al. [86] | CD aged 65+ | CUA/US healthcare payerd | Exercise (2); HAM; MF int. (2); Med. mod.; Vit. D | BD/1 yeare |
18 | Hektoen et al. [98] | CD women aged 80+ | CEA/Soc | Exercise | BD/1Â year |
19 | Hiligsmann et al. [101] | Aged 60+ with osteoporosis | CUA/Soc | Vit. D and calcium | Markov patient/lifetime |
20 | Hirst et al. [123] | Women 75+ on pain medication | CUA/PS | Med. mod. | Markov patient/1Â year |
21 | Honkanen et al. [119] | Adults aged 65+, CD at baseline | CUA; ROI/Soc | Hip protectors | Markov cohort/lifetime |
22 | Howland et al. [87] | CD aged 65+, fall admitted to A&E | ROI/US healthcare payerd | MC int | BD/1Â year |
23 | Ippoliti et al. [112] | CD aged 65+, mountainous areas | ROI/PS | MF int. | BD/3Â years |
24 | Johansson et al. [107] | CD aged 65+ | CUA/Soc | Intersectoral (MC) int.f | Markov cohort/lifetime |
25 | Lee et al. [147] | CD aged 65–80, no falls history | CBA/PS | Vit. D [targeted vs. universal] | DT + Markov cohort/3 years |
26 | Ling et al. [88] | CD aged 65+, falls history/risk factors | ROI/US healthcare payerd | HAM | BD/1Â year |
27 | McLean et al. [148] | CD aged 70+ | CEA; CUA/PS | Exercise | DT/18Â months |
28 | Miller et al. [106] | CD aged 50+ at high falls risk | ROI/US healthcared; Soc | MC int. | BD/2Â years |
29 | Mori et al. [95] | CD women 65+, no osteoporotic fracture | CUA/Soc | Exercise [alone or with bisphosphonate] | DT + Markov patient/lifetime |
30 | Moriarty et al. [120] | CD aged 65, no adverse events from benzodiazepine/PPI | CUA/PS | Med. mod. | DT + Markov patient/35 years |
31 | Nshimyu-mukiza et al. [113] | Women aged 40+ (subgroup 65+) | CEA; CUA/PS | Fracture risk screening + physical activity, Vit. D and calcium, and/or Osteoporosis screening and treatment | DT + Markov patient/lifetime |
32 | OMAS [114] | CD aged 65+ | CEA; ROI/PS | Exercise; HAM; Vit. D and calcium; Med. mod.; gait-stabilizer | Markov cohort/lifetime |
33 | Pega et al. [111] | CD aged 65+ | CUA/PS | HAM | Markov cohort/lifetime |
34 | Poole et al. [149] | Aged 65+ | ROI/PS | Vit. D | BD/1Â year |
35 | Poole et al. [150] | CD aged 60+ | CUA; ROI/PS | Vit. D | Markov cohort/5Â years |
36 | PHE [116] | CD aged 65+ | CUA; ROI/PS | Exercise (3); HAM | DT/2Â years |
37 | RCN [84] | CD aged 60+ | CUA/PS | Exercise; MF int. | Markov cohort/lifetime |
38 | Sach et al. [99] | Women 70+, bilateral cataracts | CEA; CUA/PS; Soc | Cataract surgery [first eye] | BD/lifetime extrapol.g |
39 | Sach et al. [100] | Women 70+, second operable cataract | CUA/PS; Soc | Cataract surgery [second eye] | BD/lifetime extrapol.g |
40 | Smith et al. [85] | Aged 65+ covered by GP and hospital | ROI/PS | FRS + MF int | Risk prediction/1 year |
41 | Tannenbaum et al. [121] | CD aged 65+ and insomnia | CUA/PS | Med. mod.; CBT | Markov cohort/5Â years |
42 | Turner et al. [124] | CD aged 65+ chronic sedative use for insomnia | CUA/PS | Med. mod. | DT + Markov cohort/1 year |
43 | van der Velde et al. [151] | CD geriatric outpatients with falls history | CEA/PS | Med. mod. | BD/1 yeare |
44 | Wilson et al. [110] | CD aged 65+ | CUA/PS | HAM | Markov cohort/lifetime |
45 | Wu et al. [102] | CD Medicare beneficiaries aged 65+ and falls history | CEA; ROI/PS; Soc | MF int. | BD/1Â year |
46 | Zarca et al. [122] | Aged 65+ without previous hip fracture | CEA; CUA/PS | Vit. D (targeted in two ways vs. universal) | DT + Markov patient/lifetime |